These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10534147)

  • 41. Effect of the serotonin receptor agonist, buspirone, on immune function in HIV-infected individuals: a six-month randomized, double-blind, placebo-controlled trial.
    Eugen-Olsen J; Benfield T; Axen TE; Parner J; Iversen J; Pedersen C; Nielsen JO
    HIV Clin Trials; 2000; 1(1):20-6. PubMed ID: 11590486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
    Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
    Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Maraviroc for previously treated patients with R5 HIV-1 infection.
    Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
    N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
    Ruiz L; Negredo E; Domingo P; Paredes R; Francia E; Balagué M; Gel S; Bonjoch A; Fumaz CR; Johnston S; Romeu J; Lange J; Clotet B;
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):229-36. PubMed ID: 11464141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.
    Hunt PW; Deeks SG; Rodriguez B; Valdez H; Shade SB; Abrams DI; Kitahata MM; Krone M; Neilands TB; Brand RJ; Lederman MM; Martin JN
    AIDS; 2003 Sep; 17(13):1907-15. PubMed ID: 12960823
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection.
    Eron JJ; Ashby MA; Giordano MF; Chernow M; Reiter WM; Deeks SG; Lavelle JP; Conant MA; Yangco BG; Pate PG; Torres RA; Mitsuyasu RT; Twaddell T
    Lancet; 1996 Dec; 348(9041):1547-51. PubMed ID: 8950881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of effectiveness of traditional herbal medicine in managing HIV/AIDS patients in South Africa.
    Tshibangu KC; Worku ZB; de Jongh MA; van Wyk AE; Mokwena SO; Peranovic V
    East Afr Med J; 2004 Oct; 81(10):499-504. PubMed ID: 15715126
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher HC; Bernasconi E; Sudre P; Leduc D; Yerly S; Perrin LH; Hirschel B
    AIDS; 1998 May; 12(8):F71-7. PubMed ID: 9631134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
    JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of clinical events on plasma HIV-1 RNA levels in persons with CD4+ T-lymphocyte counts of more than 500 x 10(6) cells/l.
    Chapman LE; Green TA; Ahmed F; Parekh BS; Rimland D; Kaplan JE; Thompson MA; Folks TM
    AIDS; 2000 Jun; 14(9):1135-46. PubMed ID: 10894277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
    Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
    AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial.
    Tasker SA; Treanor JJ; Paxton WB; Wallace MR
    Ann Intern Med; 1999 Sep; 131(6):430-3. PubMed ID: 10498559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Daily Nutritional Supplementation with Vitamin D₃ and Phenylbutyrate to Treatment-Naïve HIV Patients Tested in a Randomized Placebo-Controlled Trial.
    Ashenafi S; Amogne W; Kassa E; Gebreselassie N; Bekele A; Aseffa G; Getachew M; Aseffa A; Worku A; Hammar U; Bergman P; Aderaye G; Andersson J; Brighenti S
    Nutrients; 2019 Jan; 11(1):. PubMed ID: 30634590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial.
    Kaiser JD; Campa AM; Ondercin JP; Leoung GS; Pless RF; Baum MK
    J Acquir Immune Defic Syndr; 2006 Aug; 42(5):523-8. PubMed ID: 16868496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.